Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Ribavirin (RBV) is a synthetic nucleoside analog structurall...
| Class:Id | Summation:9754913 |
|---|---|
| _displayName | Ribavirin (RBV) is a synthetic nucleoside analog structurall... |
| _timestamp | 2022-01-16 09:07:48 |
| created | [InstanceEdit:9755067] Stephan, Ralf, 2021-10-05 |
| modified | [InstanceEdit:9761905] Stephan, Ralf, 2022-01-16 |
| text | Ribavirin (RBV) is a synthetic nucleoside analog structurally related to guanine. It is given orally as part of the treatment of HCV infection, and by inhalation for the treatment of RSV infection. According to the WHO, ribavirin can also be used for the treatment of viral hemorrhagic fevers (WHO 2015). RBV is administered orally in doses of 400 to 600 mg. It is highly soluble in water and a typical dose is dissolved completely over a wide range of acidities. RBV is rapidly absorbed into the circulation. After the oral administration of 600 mg radiolabeled ribavirin, approximately 61% of the drug was detected in the urine and 12% was detected in the feces. 17% of an administered dose was in unchanged form. RBV accumulates in human erythrocytes and remains in the body for weeks, with a halflife of >100 hours (Goodarzi et al, 2016). A consequence of the accumulation in erythrocytes is the well-known side effect of hemolytic anemia, which is reversible by cessation of administration (FDA label Rebetol, 2013). Ribavirin is a prodrug. It is metabolized through two different paths: phosphorylation, yielding the active triphosphate (RBV-TP), and degradation via de-ribosylation and hydrolysis of the amide group. The GI tract, and not the liver, appears to be the major site of first-pass elimination (Dixit and Perelson, 2006). |
| (summation) | [Pathway:9755088] Ribavirin ADME [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Ribavirin (RBV) is a synthetic nucleoside analog structurall... (9754913)
